C. H. ROBINSON WORLDWIDE, INC. (CHRW) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001043277 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 29, 2026 | $4.93B | $186.8M | $1.56 | Filing |
| Mar 31, 2026 | Apr 29, 2026 | $4.01B | $147.2M | $1.22 | Filing |
| Dec 31, 2025 | Jan 28, 2026 | $3.91B | $136.3M | $1.12 | Filing |
| Sep 30, 2025 | Oct 29, 2025 | $4.14B | $163.0M | $1.34 | Filing |
| Jun 30, 2025 | Jul 30, 2025 | $4.14B | $152.5M | $1.26 | Filing |
| Mar 31, 2025 | Apr 30, 2025 | $4.05B | $135.3M | $1.11 | Filing |
| Dec 31, 2024 | Jan 29, 2025 | $4.18B | $149.3M | $1.23 | Filing |
| Sep 30, 2024 | Oct 30, 2024 | $4.64B | $97.2M | $0.80 | Filing |
What would C. H. ROBINSON WORLDWIDE, INC. have to report for its valuation to change?
At $139.49, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 17.9% a year, to $11.92. On that path the next quarter needs diluted EPS near $1.58, against $1.34 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 17.9% | 17.9% |
| EPS needed in final year | $11.92 | $11.92 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. CHRW goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.